
-
Compugen NasdaqCM:CGEN Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer. Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and Gilead Sciences, Inc. for the research, development, manufacturing, and commercialization of COM503 and other products. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
Location: Azrieli Center, Holon, 5885849, Israel | Website: https://cgen.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
40.26M
Cash
103.7M
Avg Qtr Burn
N/A
Short % of Float
1.70%
Insider Ownership
2.12%
Institutional Own.
18.14%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Rilvegostomig (PD-1/TIGIT) Details Cancer, Biliary Tract Cancer | Phase 3 Data readout | |
Rilvegostomig (PD-1/TIGIT) Details Cancer, Biliary Tract Cancer | Phase 2b Data readout | |
Rilvegostomig (PD-1/TIGIT) Details Non-small cell lung carcinoma, Cancer, Hepatobiliary cancer | Phase 2 Data readout | |
COM701 + Opdivo (nivolumab) +/- BMS-986207 Details Endometrial cancer, Cancer, Ovarian cancer | Phase 1/2 Update | |
COM701 + Opdivo (nivolumab) Details Cancer, Solid tumor/s, Metastatic breast cancer | Phase 1b Update | |
COM902 (TIGIT) Details Cancer, Advanced malignancies | Phase 1 Data readout | |
COM701+COM902 +Pembrolizumab Details Cancer, Platinum-resistant ovarian cancer | Phase 1 Data readout | |
COM701+COM902 +Pembrolizumab Details Cancer, Colorectal cancer | Phase 1 Update | |
COM503 Details Cancer, Solid tumor/s | Phase 1 Initiation | |
COM701 (PVRIG) Details Ovarian cancer, Colorectal cancer , Non-small cell lung carcinoma, Breast cancer, Endometrial cancer, Cancer | Failed Discontinued |